Drug Science, Policy and Law
September 1, 2025
David Nutt, David Erritzøe, Anne Katrin Schlag et al.
9 citations
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...
Neuroscience Applied
2025
Matthias E. Liechti, Peter Gasser, Helena Aicher et al.
16 citations
This article describes the Swiss limited access program for psychedelic/3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy. The Swiss Federal Office of Public Health can issue authorizations for the limited medical use of otherwise prohibited substances. To be eligible, patients suffer from a mostly incurable disease, the prohibited substance can alleviate the suffering, and there are no...
Open Access Government
July 10, 2023
Tadeusz Hawrot
Tadeusz Hawrot, Founder and Executive Director of PAREA, states the case for a new focus in the EU’s mental health care approach, that is the underserved area of psychedelic therapies. As we navigate deeper into the 21st century, the importance of mental health care is gaining increasing recognition. But we still have a long way to go. The OECD estimates that mental illness affects one in two...
Open Access Government
January 6, 2023
Tadeusz Hawrot, David R. Badcock
Brain health conditions: Excellence in psychedelic treatments Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out. Mental healthcare is in crisis, and we don't have the tools to truly help millions of Europeans in need. In the EU, a shocking number of over 100 million people are affected by mental health conditions and alcohol use...